Dublin

Falcon Oil & Gas Ltd. - Assignment of Canadian Working Interests

Retrieved on: 
Monday, February 22, 2021
Communication, Forward-looking statement, System for Electronic Document Analysis and Retrieval, Articles, Canadian securities regulation, Information, SEC filings

This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict.

Key Points: 
  • This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict.
  • Actual results might differ materially from results suggested in any forward-looking statements.
  • Falcon assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Falcon.
  • Additional information identifying risks and uncertainties is contained in Falcons filings with the Canadian securities regulators, which filings are available at www.sedar.com.

Falcon Oil & Gas Ltd. - Granting of stock options

Retrieved on: 
Friday, February 19, 2021
Cars, Ford Falcon, Sedans, Shale gas by country

About Falcon Oil & Gas Ltd.

Key Points: 
  • About Falcon Oil & Gas Ltd.
    Falcon Oil & Gas Ltd is an international oil & gas company engaged in the exploration and development of unconventional oil and gas assets, with the current portfolio focused in Australia, South Africa and Hungary.
  • Falcon Oil & Gas Ltd is incorporated in British Columbia, Canada and headquartered in Dublin, Ireland with a technical team based in Budapest, Hungary.
  • Falcon Oil & Gas Australia Limited is a c. 98% subsidiary of Falcon Oil & Gas Ltd.
    For further information on Falcon Oil & Gas Ltd. please visit www.falconoilandgas.com
    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
  • This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict.

Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218

Retrieved on: 
Wednesday, February 17, 2021
Health sciences, Health, Amphetamine, Narcolepsy, Pharmaceutical industry in China, Pharmaceutical industry

In this role his responsibilities will include leading all aspects of the U.S. commercial launch of the companys lead program, once-nightly FT218, pending regulatory approval.

Key Points: 
  • In this role his responsibilities will include leading all aspects of the U.S. commercial launch of the companys lead program, once-nightly FT218, pending regulatory approval.
  • Richard joins our team at an important point in the companys history, said Greg Divis, Chief Executive Officer of Avadel.
  • I was drawn to Avadel because of the potential its investigational, once-nightly FT218 product offers as a game changing therapy for patients living with narcolepsy, said Mr. Kim.
  • Prior to joining Avadel, he was at Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), where he most recently served as the President of U.S. Commercial & Strategic Marketing.

Ross Stores Announces Fourth Quarter and Fiscal 2020 Earnings Release and Conference Call

Retrieved on: 
Tuesday, February 16, 2021
Economy of New York City, NASDAQ, Finance

Dublin, California -- Ross Stores, Inc. (NASDAQ: ROST) plans to release its fourth quarter and fiscal 2020 earnings results on Tuesday, March 2, 2021 at approximately 4:00 p.m. Eastern time.

Key Points: 
  • Dublin, California -- Ross Stores, Inc. (NASDAQ: ROST) plans to release its fourth quarter and fiscal 2020 earnings results on Tuesday, March 2, 2021 at approximately 4:00 p.m. Eastern time.
  • Participants may listen to a real-time audio webcast of the conference call on Tuesday, March 2, 2021 at 4:15 p.m. Eastern time by visiting the Investors section of the Companys website located at www.rossstores.com.
  • A recorded version of the call will also be available at the website address, as well as via a telephone recording at 404-537-3406, Passcode #6207398, through 8:00 p.m. Eastern time on March 9, 2021.

Middle East & Africa Upcoming Rail Projects Report 2020: An Estimated Investment of Over $530 Billion - Approx 9,100 km of Rail Length & 1,630 Stations/Stops

Retrieved on: 
Monday, February 15, 2021
Dublin, Leinster, Geography of Ireland, Geography of Europe, Tourism in Ireland

DUBLIN, Feb. 15, 2021 /PRNewswire/ -- The "Upcoming Rail Projects & Market Opportunities in the Middle East & Africa 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 15, 2021 /PRNewswire/ -- The "Upcoming Rail Projects & Market Opportunities in the Middle East & Africa 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report tracks 143 new and upcoming projects in 26 countries.
  • Some of the key highlights of the report are:
    These projects require an estimated investment of over USD530 billion.
  • Nearly 9,100 km of rail length is planned to be built as part of these projects.

Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Wednesday, February 10, 2021
Psychoactive drugs, Branches of biology, Sleep disorders, Neurochemistry, Sodium oxybate, Narcolepsy, gamma-Hydroxybutyric acid, Cataplexy, Excessive daytime sleepiness, SVB Leerink, Pharmaceutical industry

DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24th to 26th.

Key Points: 
  • DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24th to 26th.
  • FT218 is an investigational, once-nightly formulation of sodium oxybate that includes Avadels MicroPump controlled-release (CR) technology.
  • FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy.
  • In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.

Falcon Oil & Gas Ltd.

Retrieved on: 
Friday, January 22, 2021
Communication, Forward-looking statement, Articles, Factoring, Economy, Finance

Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking information.

Key Points: 
  • Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking information.
  • This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict.
  • Readers are cautioned that the foregoing list of important factors is not exhaustive and that these factors and risks are difficult to predict.
  • Falcon assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Falcon.

Falcon Oil & Gas Ltd. - Notification of Discovery - Kyalla 117 N2-1H ST2

Retrieved on: 
Tuesday, January 19, 2021
Articles, Actuarial science, Financial risk, Risk, Prediction, Academic disciplines, Forward-looking statement

Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking information.

Key Points: 
  • Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking information.
  • This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict.
  • While encouraging, readers are cautioned not to place reliance on such rates in calculating the aggregate production for Falcon.
  • Such rates are based on field estimates and may be based on limited data available at this time.

Dalata Hotel Group PLC: Notice of EGM

Retrieved on: 
Tuesday, January 5, 2021
Corporate law, Extraordinary general meeting, Meetings, Shareholders, Geography of Europe, Dalata Hotel Group, EGM, Sandyford, Articles, D18, Dublin, Companies

Dalata Hotel Group confirms that an Extraordinary General Meeting (the EGM) of the Company will be held at Burton Court, Burton Hall Drive, Sandyford, Dublin D18 Y2T8, Ireland on 29 January 2021 at 11:30am.

Key Points: 
  • Dalata Hotel Group confirms that an Extraordinary General Meeting (the EGM) of the Company will be held at Burton Court, Burton Hall Drive, Sandyford, Dublin D18 Y2T8, Ireland on 29 January 2021 at 11:30am.
  • The circular which includes the notice of the EGM (the Circular) and a Form of Proxy have been posted to shareholders today.
  • We are closely monitoring the COVID-19 situation and will take all recommendations and applicable law into account in the conduct of the EGM.
  • Any relevant updates regarding the EGM, including any changes to the arrangements outlined in the Circular, will be announced via a Regulatory Information Service and will be available onwww.dalatahotelgroup.com.